Abstract:Histone deacetylase inhibitors (HDACi) such as trichostatin A (TSA) and Sodium Butyrate (NaB) can regulate gene expression by acetylating histones and transcription factors. HDACi attenuate expression of certain NF-kB-regulated cytokines, including TNF-α, IL-1β, IL-6, and IFN-γ in some inflammatory disease models. Human tissue fatctor (TF) expression is, in part, governed by a unique, NF-kB-related “TF-kB” promoter binding site. We hypothesized that HDACi would inhibit induction of TF expression by physiologic agonists. We assessed the effect of TSA and NaB upon TF expression in human umbilical vein endothelial cells (HUVEC) and peripheral blood mononuclear cells (PBM) in response to 1 ng/ml TNF-α, 1 ng/ml IL-1β, 1 μg/ml LPS, and 100 μM HOSCN, a potent phagocyte peroxidase-derived oxidant. HUVEC monlayers and PBM were pretreated with TSA (0.01–1 μM) or NaB (1–10 mM) for 4 h prior to agonist addition and 4 h later whole cell lysates were assayed for TF activity by 1-stage clotting assay and western blots probed for TF. Both TSA and NaB inhibit HUVEC TF activity and protein expression up to 90% with respective IC50's of 30–50 nM and 2 mM. TSA decreases PBM TF activity induced by LPS and IL-1β by 50–65% with similar potency. In striking contrast, western blots show no effect of TSA on agonist-induced expression of the NF-kB-regulated adhesion molecules ICAM-1 and E-selectin. RT-PCR analysis shows TNF-α stimulation induces a 22-fold increase of TF mRNA that is attenuated up to 70% by TSA treatment without affecting the 10-fold ICAM-1 mRNA increase. TSA did not influence TF translational efficiency as detected by polyribosomal TF mRNA distribution and TSA TF inhibition was unaffected by the ubiquitin-dependent protein degradation inhibitor MG-132. EMSA analysis of HUVEC nuclear extracts using probes for the SP1, AP-1, Egr-1 and TF-kB transcription factor binding sites in the TF gene promoter shows that SP1, AP-1 and Egr-1 are constitutively activated in HUVEC and are unaffected by LPS or TNF-α irrespective of whether TSA is present. However, both TNF-α and LPS induce abundant p65/p50 and p65/c-Rel heterodimer binding to both the NF-kB and TF-kB probes. 0.3 μM TSA nearly completely abolishes TF-kB activation without affecting NF-kB activation. TSA has no effect on TNF-α-induced cytoplasmic IkB-α degradation or nuclear translocation of c-Rel, p65, or p50. Chromatin immunoprecipitation assay shows that TSA strongly inhibits p65 binding to the authentic endogenous HUVEC TF-kB site in the TF promoter induced by TNF-α without affecting p65 binding to the ICAM-1 NF-kB site. A HUVEC promoter-luciferase reporter system confirms the complete specificity of TSA's inhibitory effect on LPS- or TNF-α- induced TF expression for TF-kB rather than NF-kB. We conclude that HDACi transcriptionally inhibit agonist-induced TF expression in human endothelial cells and monocytes by specific blockade of TF-kB activation. We propose that histone deacetylases play a previously unsuspected role in regulating TF expression and HDACi might be a novel therapy for thrombotic diseases.

Histone Deacetylase Inhibitors Suppress TF-κB-dependent Agonist-driven Tissue Factor Expression in Endothelial Cells and Monocytes

“Tf-Kb”-dependent Suppression of Agonist-Mediated Tissue Factor Induction by Histone Deacetylase Inhibitors in Human Endothelial Cells and Monocytes.

Effects of trichostatin A on the expressions of inflammatory cytokines and toll-like receptor 4 and the acetylation of nuclear factor-κB induced by lipopolysaccharide in macrophage

Inhibition of Histone Deacetylases Prevents Cardiac Remodeling After Myocardial Infarction by Restoring Autophagosome Processing in Cardiac Fibroblasts.

Histone Deacetylase 3 Facilitates TNFα-mediated NF-κB Activation Through Suppressing CTSB Induced RIP1 Degradation and is Required for Host Defense Against Bacterial Infection

Tanshinone II A Attenuates TNF-α-Induced Expression of VCAM-1 and ICAM-1 in Endothelial Progenitor Cells by Blocking Activation of NF-κB.

Role of toll-like receptor 4 on tissue factor regulation in human monocytes

[The Effects of a Histone Deacetylase (HDAC) Inhibitor on Endotoxin-Induced Endothelial Cell Injury].

HDAC3 Mediates the Inflammatory Response and LPS Tolerance in Human Monocytes and Macrophages

A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture

Trichostatin A inhibits dendritic cell maturation through down-regulating NF-κ B (p65) pathway

Acadesine Inhibits Tissue Factor Induction and Thrombus Formation by Activating the Phosphoinositide 3-Kinase/akt Signaling Pathway

Inhibition of Histone Deacetylase Activity Suppresses IFN-γ Induction of Tripartite Motif 22 Via CHIP-mediated Proteasomal Degradation of IRF-1.

Promoter specific sensitivity to inhibition of histone deacetylases: implications for hormonal gene control, cellular differentiation and cancer

Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes

Histone Deacetylase Isoforms Regulate Innate Immune Responses by Deacetylating Mitogen-Activated Protein Kinase Phosphatase-1.

The Histone Deacetylase Inhibitor Tubacin Mitigates Endothelial Dysfunction by Up-Regulating the Expression of Endothelial Nitric Oxide Synthase

Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase.

Histone deacetylase inhibition suppresses the transforming growth factor β1–induced epithelial‐to‐mesenchymal transition in hepatocytes

Constitutive and Tumor Necrosis Factor-Alpha-stimulated Activation of Nuclear Factor-Kappab in Immortalized Endometriotic Cells and Their Suppression by Trichostatin A.

Trichostatin A Inhibits the Activation of Hepatic Stellate Cells by Increasing C/EBP-α Acetylation in Vivo and in Vitro.